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A COMPARATIVE STUDY ON SERUM LEVELS OF NITRIC OXIDE BEFORE 
AND AFTER INITIAL PERIODONTAL THERAPY IN HEALTHY AND                            
TYPE 2 DIABETES MELLITUS PATIENTS WITH CHRONIC PERIODONTITIS 
ABSTRACT 
Background 
Abnormal nitric oxide (NO) synthesis has been implicated in the pathogenesis of 
both periodontal disease and diabetes mellitus. Nitric oxide (NO) is a highly reactive, free 
radical which has complex roles in both health and disease. Nitric oxide (NO) is both 
harmful and beneficial to the general pathophysiology of tissues. When iNOS is released 
simultaneously with superoxide it forms the reactive nitrogen species peroxynitrite anion. 
This peroxynitrite is believed to be responsible for many of the cytotoxic effects. 
Aim of the study 
To evaluate serum levels of nitric oxide in healthy, chronic periodontitis and 
chronic periodontitis patients with type 2 diabetes mellitus before and after  initial 
periodontal therapy.  
Objectives of the study 
1) To find out the effect of initial periodontal therapy on serum levels of nitric oxide 
in healthy, chronic periodontitis and chronic periodontitis patients with type 2 
diabetes mellitus 
2) To evaluate whether nitric oxide is an indicator of the inflammatory status of 
periodontium 
 IX 
 
Materials and methods  
This was an interventional study including a total of 90 (30 healthy controls, 30 
chronic periodontitis and 30 chronic periodontitis with type 2 diabetes mellitus) subjects. 
Clinical parameters (OHI-S, GI, PPD and CAL) were recorded at baseline and 4 weeks 
after initial periodontal therapy. Initial periodontal therapy included oral hygiene 
instructions and full mouth subgingival scaling. 5ml of venous blood sample was 
collected from each subject at baseline and four weeks after initial periodontal therapy. 
Serum nitric oxide (NO) levels were assayed by Griess colorimetric reaction. Optical 
density was measured at 545 nm using a spectrophotometer. 
Results 
The periodontal parameters- Oral Hygiene Index-Simplified(OHI-S), Gingival 
Index (GI)- in all the three groups showed a marked reduction at the end of four weeks 
following initial periodontal therapy from its baseline values. No pronounced reduction 
was observed in the mean values of  probing pocket depth (PPD) and clinical attachment 
level (CAL) from its baseline values at the end of four weeks. However there was a 
statistically significant reduction in the serum levels of nitric oxide at the end of four 
weeks in all the three groups. Simultaneous comparison of pre treatment and post 
treatment periodontal parameters and serum levels of nitric oxide between the three 
groups showed that the mean values of group II and group III were higher when 
compared to group I. However comparison of the pretreatment  mean value of Gingival 
Index (GI) alone was statistically significant between group II and group III. Similarly 
the post treatment mean values of Oral Hygiene Index-Simplified(OHI-S), Gingival 
 X 
 
Index (GI) and serum levels of nitric oxide were statistically significant between group II 
and group III. 
Conclusion 
Serum levels of NO are elevated in individuals with chronic periodontitis and 
chronic periodontitis with type 2diabetes mellitus. This study provides evidence that 
initial periodontal therapy contributes to reduction in serum levels of NO in these 
patients. Larger controlled trials are needed to confirm these findings. 
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Periodontal diseases are chronic inflammatory diseases of the supporting 
tissues of the teeth caused by specific microorganisms or groups of specific 
microorganisms, resulting in progressive destruction of periodontal ligament, alveolar 
bone with pocket formation, recession or both. The balance between periodontal 
stability ("health") and periodontal breakdown ("disease") is tipped toward disease by 
risk factors, excessive production of inflammatory cytokines and enzymes, under 
activity or over activity of aspects of the immune-inflammatory host response, poor 
compliance, and a pathogenic microflora.
1
  
The concept concerning the etiology of periodontal disease considers three 
groups of factors which determine whether active periodontal disease will occur:  a 
susceptible host, the presence of pathogenic species, and the absence of so-called 
"beneficial bacteria". It is generally accepted that the oral biofilm in association with 
anaerobic bacteria is the main etiological factor in periodontal disease.
2
 Bacterial 
species in plaque biofilm including Aggregatibacter actinomycetemcomitans; 
Porphyromonas gingivalis, Treponema denticola, Fusobacterium nucleatum and 
Tannerella forsythia have been strongly associated with periodontitis. They destroy 
the periodontal tissues by both direct and indirect mechanisms. Once the bacterial 
virulence factors (lipopolysaccharide cell wall and endotoxins) have overwhelmed the 
local defense mechanisms, they stimulate a myriad of reactions in the host, resulting 
in loss of soft connective tissue elements and bone resorption.
3
 
A diverse range of endogenous chemical mediators orchestrates the host 
response and controls the inflammatory response. These chemical signals regulate the 
traffic of leukocytes and control the leukocyte response. The classic eicosanoids such 
as prostaglandins and leukotrienes exert a wide range of actions and play a key role in 
inflammation. The chemical mediators include novel lipid mediators, new cytokines, 
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chemokines, gases such as nitric oxide and carbon monoxide, reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) etc. The initial host response is the release 
of reactive oxygen species (ROS) and reactive nitrogen species (RNS) via the 
metabolic process of "respiratory burst" in the Polymorphonuclear neutrophils 
(PMNs), macrophages and monocytes.  Excessive production of these reactive species 
creates oxidative stress in the body. The reactive oxygen species (ROS) include 
oxygen-derived free radicals (e.g., superoxides, hydroxyl, peroxyl, alkoxyl) and non 
radical compounds (e.g., hypochlorus acid, ozone, singlet oxygen and hydrogen 
peroxide). Reactive nitrogen species (RNS) include nitric oxide (NO), peroxynitrite 
(ONOO
-
), nitrogen dioxide radicals and products arising from the reaction of NO with 
oxygen-free radicals.
4
   
Diabetes mellitus is a metabolic disorder characterized by hyperglycemia and 
insufficiency of secretion or action of endogenous insulin and is an established risk 
factor for periodontitis.
5
 There are two main types of diabetes,  a) Type I diabetes 
mellitus - Three interlocking mechanisms are responsible for the islet cell destruction: 
genetic susceptibility, auto-immunity, environmental insult; b) Type-2 diabetes 
mellitus - The two metabolic defects characterizing type-2 diabetes mellitus are 1) 
derangement of insulin secretion that is delayed or is insufficient relative to glucose 
load and 2. inability of peripheral tissues to respond to insulin - called insulin 
resistance.
6
 Diabetes mellitus is associated with a number of complications directly 
resulting from hyperglycemia. The hyperglycemic state is also associated with 
activated innate immunity, which is characterized by higher levels of inflammatory 
cytokines including tumor necrosis factor-α (TNF-α), interleukin-1β( IL-1β), and 
interleukin- 6 (IL-6). Hyperglycemia can affect cell-signaling transduction, in 
particular, activation of diacylglycerol and protein kinase C, which are important 
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signaling molecules responsible for cell function. Hyperglycemia is also shown to 
increase the oxidative stress via protein kinase C-dependent activation of 
nicotinamide adenine dinucleotide diphosphate (NADPH) oxidase
7,8,9
 (an enzyme that 
catalyzes superoxide and peroxide generation) in neutrophils
7,10
 and other 
phagocytes.
7,11
 Oxidative stress is thought to play a causative role in the pathogenesis 
of diabetes and its complications and has been shown to increase insulin resistance 
both in animal models and in diabetic patients.
7,12,13,14
 It was postulated that high 
glucose could activate reactive oxygen species via multiple processes, such as 
enhanced formation of advanced glycation products (AGE), dysfunction of the 
mitochondrial electron transport chain, and activation of the plasma membrane 
NADPH oxidase.
7,12,15
 Among these possibilities, NADPH oxidase is considered as 
the most important potential source of reactive oxygen species production in 
diabetic/hyperglycemic conditions.
7,9
 
The physiologic and pathologic changes in the human body depend on free 
radical and reactive oxygen species interactions to maintain normal cellular 
activities.
16 
 Oxygen and nitrogen reactive species are involved in a large number of 
physiological and pathological processes including periodontal disease and diabetes. 
Nitro-oxidative stress represents all the oxidative damages induced by reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) on the cell membranes.
17
  
Individuals with periodontal disease have an imbalance between oxidants and 
antioxidants. Following bacterial antigen stimulation, reactive oxygen species (ROS) 
or free radical molecular species are generated by polymorphonuclear neutrophils 
(PMNs), as a result of the inflammatory tissue response mechanisms. These 
mechanisms have been implicated in reactive oxygen species (ROS) involvement in 
periodontal disease, including the possible interactions of polymorphonuclear 
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neutrophils (PMNs) with respect to the level of oxidation products and transition 
metal ions, neutrophil dysfunction, and antioxidant levels.
16
 
In diabetes, free radicals are formed disproportionately by glucose oxidation, 
nonenzymatic glycation of proteins, and the subsequent oxidative degradation of 
glycated proteins. Abnormally high levels of free radicals and the simultaneous 
decline of antioxidant defense mechanisms can lead to damage of cellular organelles 
and enzymes, increased lipid peroxidation, and development of insulin resistance.
18
     
Reactive nitrogen species (RNS) consist of the nitric oxide free radical and its 
products. Nitric oxide (NO) is an important short-lived, reactive free radical molecule. 
The arrangement of one atom of nitrogen and one of oxygen leaves an unpaired 
electron, which makes the molecule a highly reactive free radical. Nitric oxide (NO) 
readily reacts with superoxide, oxygen and thiol groups (-SH) to produce a number of 
other products, such as nitrothiols (R-SNO), the toxic molecule- peroxynitrite 
(ONOO-) and nitrites.
19
 NO is synthesized from L-Arginine by a complex family of 
enzymes called nitric oxide synthases (NOS).
20 
 NOS is one of the most regulated 
enzymes in biology. Three different isoforms are known - endothelial NOS (eNOS), 
brain or neuronal NOS (bNOS), inducible NOS (iNOS).
 21
  
NO can readily diffuse through cytoplasm and plasma membrane due to its 
solubility in both aqueous and lipid environments.
22
 NO does not bind to receptors 
and its effects are transient. It gets readily oxidized and remains stored in tissues as 
nitrates (NO3
-
) or nitrites (NO2
-
).
23
 NO in low concentration helps in the normal 
physiological process. It mainly acts as a biological messenger and takes important 
roles in vasodilatation, immunomodulation, regulation of mineralized tissue function, 
neurotransmission, platelet aggregation and antimicrobial action.
23, 24, 25, 26
 Nitric 
Introduction 
 
 5 
 
oxide (NO) produced in high concentrations proves to be crucial in non-specific host 
defense and is cytotoxic.
23
 
 When iNOS is released simultaneously with superoxide, it forms the reactive 
nitrogen species peroxynitrite anion (ONOO-). This peroxynitrite is believed to be 
responsible for many of the cytotoxic effects previously attributed to nitric oxide and 
superoxide. These activities include: lipid peroxidation; glutathione depletion by 
oxidation; nitrotyrosine formation which may inhibit superoxide dismutase activity; 
DNA damage by nitrosilation, deamination and oxidation; high concentrations cause 
rapid cellular necrosis.
27
  
Estimation of nitrate and nitrite, the stable end products of nitric oxide 
production, is a common indirect method used to monitor nitric oxide levels in 
various biological fluids.
28,29
 Endogenous nitric oxide (NO) production is highly 
correlated with nitrite and nitrate levels in serum and plasma.
28
 
Abnormal nitric oxide synthesis has been implicated in the pathogenesis of 
both periodontal disease and diabetes mellitus.
30
 Till date, there are only limited data 
concerning the influence of serum levels of Nitric oxide (NO) in the inflammatory 
reactions of the periodontium in chronic periodontitis patients with type 2 diabetes 
mellitus after initial periodontal therapy.  Hence an attempt has been made in this 
study to evaluate and compare the serum levels of nitric oxide in healthy, chronic 
periodontitis and chronic periodontitis patients with type 2 diabetes mellitus before 
and after initial periodontal therapy. 
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Aim of the study 
To evaluate serum levels of nitric oxide in healthy, chronic periodontitis and 
chronic periodontitis patients with type 2 diabetes mellitus before and after  initial 
periodontal therapy.  
Objectives of the study 
1) To find out the effect of initial periodontal therapy on serum levels of nitric 
oxide in healthy, chronic periodontitis and chronic periodontitis patients with 
type 2 diabetes mellitus 
2) To evaluate whether nitric oxide is an indicator of the inflammatory status of 
periodontium 
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Periodontal disease and diabetes are strongly interrelated and have common 
pathobiology. Inflammatory events during periodontal disease may play an important 
role in development of diabetes and insulin resistance probably facilitates the progress 
of periodontal disease. Both diseases can modulate host immune response, such as 
upregulation of inflammatory cell phenotype, elevation of proinflammatory cytokines, 
and initiation of tissue damage. The outcome of activation of the inflammatory 
response in both diseases is similar in many aspects. The inflammatory response in 
diabetes is diverse, complicated, and affects a multitude of tissues and organs. The 
pathways of vascular tissue complications in diabetes are mediated through the 
formation of advanced glycation end products (AGE), and increased production of 
reactive oxygen species by both activation of the diacylglycerol–protein kinase C 
pathway 
7,31 
or increased activation of the polyol pathway.
7,32
 The interaction between 
these mechanisms in the periodontium with pre-existing periodontal disease provides 
insight into the exacerbated periodontal destruction in diabetics, and also may explain 
why diabetic patients are at greater risk for periodontitis.
 
 Oxidative stress is one of the main factors studied to explain the 
pathophysiological mechanisms of inflammatory conditions, such as diabetes and 
periodontitis. It seems that peripheral blood neutrophil hyperactivity in chronic and 
aggressive periodontitis exists as a constitutional element, rather than being entirely 
the result of peripheral priming by cytokines or plaque bacterial LPS. In addition, 
there may be possible baseline hyperactivity, with low-level extracellular ROS release 
in the absence of any exogenous stimulus in persons with periodontitis. Increased pro-
oxidative state and decreased anti-oxidant capacity in persons with periodontitis could 
facilitate the onset of a decrease in insulin sensitivity. The presence of a high RAGE 
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expression in periodontal tissues is an important finding supporting the sensitivity of 
these tissues to products derived from oxidative damage. Moreover, AGE may 
promote apoptosis in osteoblasts and fibroblasts, and this might have an influence on 
alveolar bone homeostasis and the progression of periodontitis.
33
 This way, it is 
plausible to draw a patho-physiological picture in which a bidirectional influence 
exists between both conditions, with oxidative stress as a common link.
 
 
Nitric oxide: A multifaceted molecule - An overview 
In 1980, Furchgott and Zawadski
34,35
 discovered that the endothelium releases 
a factor that relaxes the underlying vascular smooth muscle. They termed this 
substance endothelium derived relaxing factor (EDRF). EDRF was identified as nitric 
oxide (NO) by Palmer et al
34, 24
 and Ignarro et al. 
34,36   
Nitric oxide (NO) is a free radical produced from L-arginine through the 
action of isoenzymes, globally named nitric oxide synthases (NOS). Three different 
isoforms are known - endothelial NOS (eNOS), brain or neuronal NOS (bNOS), 
inducible NOS (iNOS).
21
These isoforms have historically been categorized based 
upon differences in their primary locations in the body, inducibility, levels of nitric 
oxide production upon activation, and calcium dependence. Neuronal NOS and 
endothelial NOS are expressed constitutively, are calcium dependent and produce low 
levels of NO upon stimulation. Conversely, iNOS is regulated at the transcriptional 
level and is shown to be induced in multiple cell types upon bacterial or cytokine 
stimulation. Inducible NOS produces high levels of NO upon stimulation.
37
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The L-arginine nitric oxide pathway 
 
NO appears to be an important regulator of various physiologic processes in both 
animals and humans. The cytotoxic effects of nitric oxide are mediated by 
peroxynitrite, a highly reactive oxidant formed from the reaction of nitric oxide with 
superoxide .
38,39
 Formation of peroxynitrite can result in both oxidative and nitrosative 
stress since it consists of both a reactive oxygen and a reactive nitrogen species.
37 
 
Pleiotropic effects of NO 
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NO is regulated by feedback inhibition of the presence of endogenous 
inhibitors such as asymmetric dimethylarginine (ADMA), and enzymes which 
compete for the substrate L-Arginine.
37,40
 Moreover, the availability of L-Arginine 
and necessary NOS cofactors, the presence of compounds which readily bind NO 
(heme,glutathione), and the modulation of transcription and translation of NOS by 
deoxyribonucleic acid (DNA) methylation or by actions of various cytokines and 
mediators also are involved in the regulation of NO production.
41 
 
Nitric oxide and diabetes mellitus 
Oxidative stress and changes in nitric oxide formation or action play major 
roles in the onset of diabetic complications. Diabetes is usually accompanied by 
increased production of free radicals or impaired antioxidant defenses. Hyperglycemia 
is also found to promote lipid peroxidation of low density lipoprotein by a 
superoxide-dependent pathway resulting in the generation of free radicals. Another 
important source of free radicals in diabetes is the interaction of glucose with proteins 
leading to the formation of an Amadori product and then advanced glycation end 
products (AGEs). These AGEs, via their receptors (RAGEs), inactivate enzymes and 
alter their structures and functions, promote free radical formation, and quench and 
block antiproliferative effects of nitric oxide. By increasing intracellular oxidative 
stress, AGEs activate the transcription factor NF-kB, thus promoting up-regulation of 
various NF-kB controlled target genes. NF-kB enhances production of nitric oxide, 
which is believed to be a mediator of islet beta cell damage.
18
 Nitric oxide may react 
with superoxide anion radical to form reactive peroxynitrite radicals. 
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1) In vitro studies 
Lindsey et al. (1996)
42
  investigated the effect of (a) insulin-treated diabetes, 
and (b) chronic in vivo administration of N
ω
-nitro-L-arginine methyl ester (L-
NAME), a NOS inhibitor, on mean arterial pressure and in vitro vascular reactivity to 
noradrenaline in mesenteric arterial bed preparations from spontaneously diabetic, 
insulin-dependent and treated BB rats, the best animal model of insulin-dependent 
mellitus. They reported that following chronic L-NAME treatment, diabetic BB/E rats 
exhibited attenuated hypertension and an absence of enhanced vascular 
responsiveness to noradrenaline in vitro compared to similarly treated non-diabetic 
rats. These results, together with the significantly impaired endothelium-dependent 
vasodilatation and unchanged endothelium-independent vasodilatation in vitro of 
preparations from diabetic BB/E rats, were consistent with the hypothesis that 
functional changes in the synthesis and metabolism of NO occur in diabetes. Their 
results indicate that good glycaemic control alone is insufficient to prevent these 
abnormalities in NO availability. 
S.N. Zykova et al. (2000)
43
 studied peritoneal macrophages from diabetic 
type 2–like db/db mice. They found that the release of  TNF-α and IL-1from 
lipopolysaccharide plus IFN-γ –stimulated macrophages and vascular endothelial 
growth factor from both stimulated and nonstimulated macrophages was signiﬁcantly 
reduced in diabetic animals compared with nondiabetic controls. Nitric oxide 
production from the stimulated db/db macrophages was signiﬁcantly higher than that 
in the db/+ cultures, whereas there was no difference in their ability to generate 
reactive oxygen species. When studied both at light and electron microscopic levels, 
macrophages in diabetic animals had an altered morphological appearance compared 
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with those of normal controls. They concluded that the function and morphology of 
the macrophages were disturbed in db/db mice due to the mechanisms underlying 
common inﬂammatory and degenerative manifestations in diabetes.  
Daghigh F. et al. (20002)
44
 assessed NO production under basal conditions or 
following incubation with TNF-α, IL-1β, and IFN-γ by measurement of stable NO 
metabolites, nitrite and nitrate, in a microplate adaptation of the Griess assay. Total 
RNA was isolated from HGF for determination of iNOS mRNA levels. NO 
production was elevated in HGF that were stimulated simultaneously by TNF-α, IL-
1β, and IFN-γ. They found that addition of Mercaptoethylguanidine (MEG), a specific 
inhibitor of iNOS, profoundly reduced the production of NO in HGF. They concluded 
that NOS2 inhibitors reduced gingival fibroblast NO production and it was postulated 
that pharmacological inhibition of NO might be therapeutically valuable in the 
management of periodontal disease. 
2) Animal studies  
Mohan I.K. et al. (1998)
45
 reported that nitric oxide levels in plasma were 
decreased in alloxan-diabetic rats, an effect that could be abrogated by prior and 
simultaneous administration of L-arginine, a precursor of nitric oxide. When N 
monomethyl- L-arginine, a specific inhibitor of nitric oxide synthase, was given along 
with alloxan, the beneficial actions of L-arginine in diabetes were blocked. When 
sodium nitroprusside and L-arginine were administered simultaneously with alloxan 
for 5 days, nitric oxide production remained at control levels. These results suggest 
that both L-arginine and sodium nitroprusside, with the capacity to enhance nitric 
oxide levels in alloxan-diabetic animals, could prevent alloxan induced islet beta-cell 
damage and the development of diabetes as well as restore the antioxidant status. 
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Komers R. et al. (2000)
46
 assessed systemic and renal hemodynamics before 
and after acute inhibition of iNOS enzyme with a specific inhibitor, S-methyl-L-
thiocitrulline, in control and diabetic rats. The interaction of this pathway and the 
renin-angiotensin system was studied in separate groups of rats pretreated with the 
angiotensin II receptor blocker losartan. They reported that  kidneys of 3 week 
diabetic rats could be further enhanced by S-methyl-L-thiocitrulline treatment, 
whereas administration of losartan along with S-L-thiocitrulline for 3–5 weeks could 
normalize the nitric oxide levels implying that angiotensin II is an important 
modulator of nitric oxide pathway in diabetes. 
3) Human studies 
Kedziora-Kornatowska K.Z. (1999)
47
 studied the production of the 
superoxide radical anion O2
-
. and the nitric oxide radical NO
-
. by granulocytes in type 
2 diabetes patients with/without diabetic nephropathy. They reported that O2
-
. 
Production by both resting and stimulated granulocytes in type 2 diabetes patients 
without nephropathy was increased but decreased in type 2 diabetes patients with 
nephropathy, compared with healthy subjects. NO
-
. generation was highly augmented 
in type 2 diabetes patients without nephropathy by both resting and stimulated cells; 
values for type 2 diabetes patients with nephropathy were intermediate between the 
type 2 diabetes patients without nephropathy and the healthy subjects. Their findings 
point to granulocytes as one of possible sources of oxidative stress in type 2 diabetes. 
Yilmaz et al. (2000)
48
 determined nitric oxide levels in the vitreous of patients 
with proliferative diabetic retinopathy, using the spectrophotometric method based on 
Griess reaction. They found that vitreous nitric oxide levels were elevated in patients 
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with proliferative diabetic retinopathy with tractional retinal detachment. Hence nitric 
oxide might play a role in the pathogenesis of proliferative diabetic retinopathy. 
Maejima K. et al. (2001)
49
  assessed the underlying mechanisms of decreased 
endothelial function and advanced vascular complications in patients with Type 2 
diabetes, by determining the basal levels of plasma nitric oxide (NOx: NO2
- 
and NO3
–
 
using a newly developed high-performance liquid chromatography (HPLC)-Griess 
method. Serum lipid peroxide and advanced glycation end products (AGEs) as 
markers of oxidative stress were also measured, and intima-media thickness (IMT) of 
the carotid artery was evaluated as a marker of atherosclerosis. In diabetic subjects, 
microvascular complications were newly evaluated during their admission. There was 
no difference in basal plasma NO2
- 
 levels between the two groups, the basal levels of 
plasma NO3
–
  in diabetic subjects were significantly higher than those in nondiabetic 
subjects. Plasma NOx levels in neither diabetic nor nondiabetic subjects correlated 
with serum lipids, HbA1c, or IMT. In diabetic subjects, plasma NO3
–
  levels were 
related not only to the presence of hypertension but also to advanced microvascular 
complications. Plasma NO3
–
  levels were positively correlated with both serum lipid 
peroxide and AGEs. Their findings were found to be consistent with the hypothesis 
that decreased endothelium-dependent vasodilation in diabetic subjects is associated 
with the impaired action of NO secondary to its inactivation resulting from increased 
oxidative stress, rather than decreased NO production from vascular endothelium, and 
that abnormal NO metabolism is related to advanced diabetic microvascular 
complications. 
M. Kawaktsu et al. (2002)
50
 analyzed nitrite /nitrate (NOx) in healthy mass 
population and investigated the relationship with gender, aging and some diabetic 
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complications. At the fasting stage, the mean value of NOx in the healthy subjects 
was 47.5±26 (μM/L), and the ratio of nitrite to nitrate was approximately 1:6. After an 
intake of celery containing rich nitric compounds, NOx markedly increased to 2.5 
times, mainly because of an increase in nitrate. In the male subjects, NOx gradually 
increased with aging, whereas in the females, it tended to decrease until the 
menopausal stage but turned upward after that. NOx in the group without any diabetic 
complication was much lower than that in the control group but the group with 
coronary artery disease showed a higher value. They concluded that  NOx  was 
influenced by exogenous factors, aging, and difference of gender, and showed some 
correlations with hyperglycemic vascular impairments. 
 Dogany N. et al. (2002)
51
 suggested that serum NO, sIL-2R, IL-8 and TNF-
alpha might play important roles in the pathophysiology and progression of diabetic 
retinopathy and these potentially inflammatory cytokines and NO with their 
endothelial implications might act together during the course and progression of 
diabetic retinopathy. These molecules could be served as therapeutic targets for the 
treatment and/or prevention of diabetes with its systemic and ocular microvascular 
complications. 
Nogueira-Machado J.A. et al. (2002)
52
  performed a study with granulocytes 
from non-diabetic subjects and from type II -Non Insulin Dependent Diabetes mellitus 
(NIDDM) patients. The NO generation was comparatively determined by the nitrite 
concentration (micromolar of nitrite) after cell incubation in the presence of cyclic 
nucleotide-elevating agents. Their results showed an inverse reactivity for 
granulocytes from diabetic patients when compared to non-diabetic subjects. They 
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also found that  both cyclic AMP and cyclic GMP were able to modulate nitric oxide 
production in human granulocytes and that cell reactivity in diabetic patients. 
Ozden S. et al. (2003)
53
 demonstrated both elevated levels of serum NOx in 
diabetic patients as compared with nondiabetic controls and a relationship between 
NOx and diabetic retinopathy severity. They concluded that abnormal NO metabolism 
might have a role in the pathogenesis of diabetic retinopathy. 
Torres et al. (2004)
54
 assessed nitric oxide generation in skeletal muscle in 
type 2 diabetic patients. They found that iNOS is increased in skeletal muscle samples 
of type 2 diabetic patients. Although iNOS was induced in muscle ﬁbres and 
endothelial cells, the presence of macrophages and the increased levels of TNF and 
CD154 were evidence of an inﬂammatory process with macrophage and T-cell 
activation. The moderate increase of the NO products NO2
-
 and NO3
-
, contrasting with 
the markedly augmented levels of nitrotyrosine, indicates that NO reacted with O2 to 
produce ONOO
- , which ﬁnally nitrated tyrosine residues. They suggested that 
superoxide ion necessary to react with NO for the
 
production of ONOO
- 
might have 
been generated in relation to AGE formation. 
S.R. Kashyap et al. (2005)
55
 determined nitric oxide synthase (NOS) activity 
in skeletal muscle of 10 type 2 diabetics (HbA1C = 6.8 ± 0.1%). They reported that 
basal and insulin-stimulated muscle NOS activity is impaired in well-controlled type 
2 diabetic subjects, and the defect in insulin-stimulated NOS activity correlated 
closely with the severity of insulin resistance and suggested that impaired NOS 
activity may play an important role in the insulin resistance in type 2 diabetic 
individuals. 
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 Izumi et al. (2006)
56
 estimated the levels of plasma NOx (nitrite and nitrate), 
the stable metabolites of NO, by high-performance liquid chromatography with the 
Griess method. They concluded that NO might be associated with the pathogenesis of 
diabetic retinopathy. 
M.H. Mahfouz et al. (2009)
57
 conducted a study to determine two 
cardiovascular  risk factors (ADMA-  asymmetric dimethylarginine  and NO) in type 
2 diabetic patients with and without cardiovascular disease and to evaluate the 
association between ADMA and HbA1c on the one hand and nitric oxide on the other 
hand. Fasting and postprandial serum glucose, HbA1c, lipid profile (total cholesterol, 
triacylglycerol, HDL-c and LDL-c), ADMA and serum NO metabolite level, were 
determined. Serum glucose (fasting and postprandial), HbA1c and ADMA levels 
showed significant increase in diabetic patients type 2 with and without 
cardiovascular complications compared to healthy normal control. Total cholesterol, 
triacylglycerol and LDL-c manifested significant elevations, while HDL-c level 
showed insignificant change in both groups in compared to non diabetic healthy 
subjects. Serum NO metabolite level was significantly reduced in the both diabetic 
patient groups compared with controls. No correlation between ADMA level and 
studied parameters in diabetic patients without evidence of cardiovascular 
complications, whereas in cardiovascular complications group, the ADMA level was 
positively correlated with both postprandial serum glucose and HbA1c, but there was 
a negative correlation between ADMA levels and NO. Also, NO was negatively 
correlated with postprandial serum glucose and HbA1c. They concluded that ADMA 
and NO might serve as predictors for future cardiovascular events in type 2 diabetic 
patients 
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 P. Tessari et al. (2010)
58
 measured nitrite/nitrate (NOx) fractional (FSR) and 
absolute (ASR) synthesis rates in type 2 diabetic patients with diabetic nephropathy 
and in control subjects, after L-[15N2-guanidino]-arginine infusion, and use of 
precursor– product relationships. They reported that  type 2 diabetic patients with 
nephropathy, intravascular NOx synthesis from arginine is decreased under both basal 
and hyperinsulinemic states. This defect might extend the concept of insulin 
resistance to NO metabolism. 
A.Ghosh et al. (2011)
59
 compared serum nitric oxide level among type 2 
diabetic patients along with other biochemical parameters. Griess reaction was used 
for indirect assay of stable decomposition products in serum (serum nitrite and nitrate 
levels) as an index of NO generation.  Serum NO was observed significantly low in 
diabetic participants as compared to control, along with difference in other 
biochemical parameters. 
 
Nitric oxide and periodontal disease 
Periodontal diseases are chronic inflammatory infections accompanied by 
destruction of surrounding connective tissue and alveolar bone. Cytokines and other 
bacterial products stimulate the expression of iNOS and interfere with periodontal 
disease progression. The primary causative agents are gram-negative bacteria, which 
stimulate cells like macrophages, fibroblasts to generate NO. More specifically, 
bacterial lipopolysaccharides stimulate NO expression in bone as well as other tissues. 
The presence of NO in periodontal disease may reflect the participation of an 
additional mediator contributing to periodontal tissue damage and bone resorption 
responsible for progression of periodontitis. The evaluation of involvement of nitric 
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oxide in the periodontal disease will enable us to understand the complexity of 
periodontal disease progression. 
1) In vitro studies  
Shapira L. et al. (2000)
60
 designed a study to examine whether the functional 
response to mouse macrophages stimulated by porphyromonas gingivalis 
lipopolysaccharide is affected by experimental stress, and to investigate the role of 
corticosterone (CS) in the stress related effects. Their results showed that 
experimental stress might modulate the response of macrophages to inflammatory 
stimulants and that CS is not the sole mediator involved. The presence of IFN-γ in the 
culture may mask the functional differences induced by stress. The stress induced 
Upregulation of NO secretion might be involved in the accelerated periodontal 
destruction in stressed subjects. 
2) Animal studies 
Z. Lohinai et al. (2001)
61
 investigated the potential role of nitric-oxide-
derived nitrating species (such as peroxynitrite) in a rat model of ligature-induced 
periodontitis. Formation of 3-nitrotyrosine, the stable product formed from tyrosine 
reacting with nitric-oxide-derived nitrating species, was detected in the 
gingivomucosal tissue. 3-Nitrotyrosine immunohistochemical analysis revealed a 
significant elevation in the number of immunopositive leukocytes, and higher 
immunoreactivity of the gingival ligaments and epithelium in the ligated than in the 
contralateral (control) side. They suggested that resident bacteria of the 
gingivomucosal tissue induce an increase in reactive nitrogen species, which might be 
greatly enhanced by plaque formation in periodontitis. 
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R.F.C. Leitao et al .(2005)
62
 conducted a study in Winstar rats subjected to a 
ligature placement around the second upper left molars and were sacrificed at 11 days. 
Alveolar bone loss was evaluated by the sum of distances between the cusp tips and 
the alveolar bone along the axis of each molar root, subtracting from the contralateral 
side. Histopathological analysis was based on cell influx, alveolar bone and 
cementum integrity. Leukogram was performed at 6 hours and 1,7,and 11 days after 
the EPD induction. Groups were treated with the NOS inhibitors, aminoguanidine 
(AG) or L-arginine methyl ester intraperitoneally, 1hour before the EPD induction 
and daily for 11 days. Results showed that both these inhibitors significantly and dose 
–dependently inhibited the alveolar bone loss . L-NAME (20mg/kg/d) reduced the 
alveolar bone loss by 50%, whereas AG (5mg/kg/d) reduced it by 47% compared to 
EPD group. 
S.Y. Fukada et al. (2008)
63
 evaluated the role of NO in bone loss in bacterial 
infection-induced apical periodontitis by using iNOS-deficient mice (iNOS
−/−
). The 
iNOS
−/−
 mice developed greater inflammatory cell recruitment and osteolytic lesions 
than WT mice. Moreover, tartrate-resistant acid-phosphatase-positive (TRAP
+
) 
osteoclasts were significantly more numerous in iNOS
−/−
 mice. Furthermore, the 
increased bone resorption in iNOS
−/−
 mice also correlated with the increased 
expression of receptor activator NF-kB (RANK), stromal-cell-derived factor-1α 
(SDF-1α/CXCL12), and reduced expression of osteoprotegerin (OPG). Their results 
showed that NO deficiency was associated with an imbalance of bone-resorption-
modulating factors, leading to severe infection-stimulated bone loss. 
Herrera B.S. et al. (2011)
64
 evaluated the alveolar bone loss in rats with 
periodontitis under long-term iNOS inhibition, and the differentiation and activity of 
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osteoclast (OC) from iNOS-knockout (KO) mice in vitro. Oral aminoguanidine (an 
iNOS inhibitor) or water treatment was started 2 weeks before induction of 
periodontitis. Rats were sacrificed 3, 7, or 14 days after ligature placement, and 
alveolar bone loss was evaluated. In vitro osteoclast culture experiments were also 
performed to study the differentiation of freshly isolated bone marrow cells from both 
iNOS KO and wild-type C57BL/6 mice. Osteoclast were counted 6 days later after 
tartrate-resistant acid phosphatase staining (a marker of osteoclast identity), and bone 
resorption activity was assessed by counting the number of resorption pits on dentin 
disks. Results demonstrated that iNOS inhibition prevents alveolar bone loss in a rat 
model of ligature-induced periodontitis. Thus they confirmed that iNOS-derived NO 
might play a crucial role in the pathogenesis of periodontitis, probably by stimulating 
osteoclast differentiation and activity. 
Herrera B.S. et al. (2011)
65
 assessed the renal and cardiac consequences of 
ligature-induced periodontitis in both normotensive and NO-deficient (L-NAME-
treated) hypertensive rats. In NO-deficient hypertensive rats, periodontitis-induced 
alveolar bone loss was significantly diminished. In addition, periodontitis-induced 
cardiac NT elevation was completely prevented by L-NAME treatment. L-NAME 
treatment enhanced MPO production in both heart and kidneys of rats with 
periodontitis. No changes due to periodontitis were observed in cardiac or renal 
thiobarbituriuc acid reactive substances (TBARS) content. They concluded that in 
addition to mediating alveolar bone loss, NO could contribute to systemic effects of 
periodontitis in the heart and kidney. 
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3) Human studies 
Kankanian and Akapov (1996)
66
 have shown that saliva from healthy 
subjects stimulates NO synthesis in PMNL, while the saliva from patients with 
gingivitis or periodontitis does not or even suppresses it. Furthermore, PMNL from 
gingival fluid or blood of patients with periodontitis, in contrast to PMNL from 
healthy subjects, inhibits NO-induced cGMP accumulation in cultured fibroblasts. 
Aurer A. et al. (2001)
67
 analysed salivary NO2
- 
concentrations in patients with 
rapidly progressive periodontitis (RPP). The concentrations of NO2
- 
were determined 
by the Griess reaction in microtitration plates. Periodontal tissue destruction was 
determined by measuring the attachment level loss using standard methods. Results 
showed that subjects with periodontitis had significantly less NO2
-
  in saliva than 
healthy subjects. Subjects with RPP had lower NO2
- 
 concentrations. Parotid gland 
saliva contained less NO2
- 
 than sublingual gland or total saliva. They concluded that 
local NO production is decreased in patients with periodontitis. This effect would be 
more pronounced in those with severe types of disease. 
Carossa et al. (2001)
68
 reported that oral NO production and salivary nitrite 
levels increased during de novo plaque deposition in periodontally healthy subjects. 
They proposed that this may be an early defense mechanism against bacterial 
proliferation in the dental plaque. They further demonstrated that this response was 
inhibited in smokers and was associated with an elevation in plaque bacterial counts 
as compared to non-smokers. 
M. Hirose et al. (2001)
69
 determined the mRNA expression of cytokines and 
iNOS in inflamed and healthy gingival tissue using polymerase chain reaction (RT-
PCR), and the relationship between their profiles and the detection of specific bacteria 
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was analyzed. They concluded that the expression of IL-6 may reflect inflammation in 
gingival tissue , and iNOS may be involved in the inflammatory process in 
periodontitis. The presence of Aggregatibacter actinomycetemcomitans or 
Porphyromonas gingivalis might relate to the different cytokine profiles of IL-1α,IL-
6,IL-8 and IL-10.  
K. Shibata et al.  (2001)
70
 examined the involvement of NOS in chemotaxis 
of normal neutrophils and NOS activity in neutrophils from normal subjects and 
patients with localized aggressive periodontitis (LAgP). Membrane associated –NOS 
and soluble NOS were extracted from cells with or without N-formyl-methionyl-
leucyl-phenylalanine (fMPLP) stimulation. NOS activity was measured using the 
radiolabeled L-arginine to L-citrulline conversion assay. They found that N
ω
-Nitro-L-
arginine methyl ester (L-NAME) and inhibitor of NOS, significantly attenuated the 
inhibition by L-NAME. Unstimulated MA-NOS activity in LAgP neutrophils was 
statistically higher than that in normal neutrophils. They suggested that NOS is 
present in human neutrophils and may be involved in fMLP- induced chemotaxis in 
neutrophils.NOS activity is increased in LAsP and is negatively correlated to 
chemotaxis response. 
In order to further characterize the presence of NO in human periodontal 
disease, Batista A.C. et al. (2002)
21
 undertook a quantitative study of iNOS positive 
cells in samples of clinically healthy gingival tissues, plaque-induced gingivitis and 
localized chronic periodontitis using immunohistochemistry. The  results indicated 
that iNOS increases in the presence of periodontal disease and  they suggested that 
polymorphonuclear cells present an additional activation pathway in periodontal 
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disease, expressing significant iNOS and probably representing an important source 
of NO in human periodontal disease. 
Sosreseno et al. (2004)
71
 determined nitric oxide (NO) production of a murine 
macrophage cell line (RAW 264.7 cells) when stimulated with Porphyromonas 
gingivalis lipopolysaccharides (Pg-LPS). RAW264.7 cells were incubated with i) 
various concentrations of Pg-LPS or Salmonella typhosa LPS (St-LPS), ii) Pg-LPS 
with or without L-arginine and/or N
G
-monomethyl-L-arginine (NMMA), an arginine 
analog or iii) Pg-LPS and IFN-γ with or without anti-IFN-γ antibodies or interleukin-
10 (IL-10). Tissue culture supernatants were assayed for NO levels after 24 h in 
culture. NO was not observed in tissue culture supernatants of RAW 264.7 cells 
following stimulation with Pg-LPS, but was observed after stimulation with St-LPS. 
Exogenous L-arginine restored the ability of Pg-LPS to induce NO production; 
however, the increase in NO levels of cells stimulated with Pg-LPS with exogenous L-
arginine was abolished by NMMA. IFN-γ induced independent NO production by Pg-
LPS-stimulated macrophages and this stimulatory effect of IFN-γ could be completely 
suppressed by anti-IFN-γ antibodies and IL-10. Their results suggest that Pg-LPS is 
able to stimulate NO production in the RAW264.7 macrophage cell model in an L-
arginine-dependent mechanism which is itself independent of the action of IFN-γ. 
Skaleric et al.  (2006)
30
 evaluated the expression of NO in gingivae of type I 
diabetic patients presenting with periodontal disease and to correlate the level of NO 
with P. Intermedia infection. They suggested that in diabetic patients, increased 
inducible NO synthase in inflamed gingiva correlated with NO in gingival crevicular 
fluid. Although increased NO reflected more-severe inflammation, it was associated 
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with reductions in colony forming units (CFU) of Prevotella intermedia, a major 
periodontopathogen, highlighting dual roles for NO. 
A. Berdeli et al. (2006)
72
 evaluated genotype distribution and genotype-
phenotype association in periodontal disease regarding Glu298Asp polymorphism of 
the eNOS gene. They showed that eNOS Glu298Asp polymorphism is associated with 
BOP in GAgP patients. Moreover, the 298Asp allele of the eNOS gene might be 
related to CP in the Turkish population.   
 K.B. Menaka et al. (2009)
23
 assessed the level of NO in serum in chronic 
periodontitis, and correlated these levels with the severity of periodontal disease. 
Results showed that subjects with periodontitis had significantly high nitrite in serum 
than healthy subjects. NO production was increased in periodontal disease. This 
finding could help to understand its role in disease progression and selective 
inhibition of NO might be of therapeutic utility in limiting the progression of 
periodontitis. 
Zeynep Pan et al. (2010)
73
 evaluated the expression of inducible nitric oxide 
synthase (iNOS) in the gingival tissues of periodontitis patients with and without type 
2 diabetes to assess whether NO plays a role in the severity of periodontitis in patients 
with diabetes. They reported that inflammation and iNOS expression were more 
prominent in the gingiva of the patients with both diabetes and periodontitis. 
However, iNOS expression did not seem to have an additional detrimental effect on 
the course of periodontitis in patients with diabetes compared to those with 
periodontitis alone. 
Ozer et al. (2011)
74
 examined the arginine-NO-polyamine pathway alteration 
in saliva and gingival biopsy samples of patients with gingivitis or periodontitis and 
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healthy controls and evaluated the response to periodontal treatment. Periodontal 
clinical measurements, gingival biopsies, and saliva samples were obtained before 
treatment and 1 month after periodontal treatment. Arginase and ornithine de 
carboxylase (ODC) activities and NO levels were determined spectrophotometrically. 
They reported  that regarding arginine-NO-polyamine metabolism, gingival tissue 
would be more informative about periodontal pathogenesis than saliva. At early phase 
of periodontal inflammation, NO arginase and ODC levels were measured as higher 
than at an established lesion of periodontitis. 
S.R. Parwani et al.  (2012)
75
 conducted a study to estimate salivary nitric 
oxide levels in inflammatory periodontal diseases. They found that NO levels were 
increased significantly in gingivitis and periodontitis subjects as compared with 
controls. They noted a statistically significant decrease in the nitric oxide levels after 
the healing period(curresponding to the reduced clinical signs of inflammation). They 
also found a positive correlation between probing pocket depths with salivary nitric 
oxide levels. They concluded that salivary nitric oxide levels could be utilized as a 
good indicator of the inflammatory status of the periodontium. 
D.H. Han et al.  (2012)
76
 investigated the relationship between salivary nitric 
oxide and periodontitis in an elderly Korean population. Periodontitis was determined 
by a clinical attachment loss of over 6mm at 6 probe points in 12 index teeth. NO was 
measured in unstimulated saliva via the Griess reaction. After controlling for age, 
gender, education, salivary flow rate, number of teeth, smoking status, physical 
activity, hypertension, and diabetes, three metabolites of salivary NO (total NO, 
nitrite, and nitrate) were independently associated with the percentage of probe points 
exhibiting periodontitis. Total NO was found to have the strongest correlation with 
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periodontitis. These associations were most pronounced in females, non-smokers 
(except for nitrate), those without hypertension and those without diabetes.  
I.S. Choi et al.  (2012)
77
 attempted to investigate the effect of kaempferol on 
the production of NO by murine macrophage-like RAW264.7 cells stimulated with 
LPS from Prevotella intermedia, a pathogen implicated in periodontal disease, and to 
determine the underlying mechanisms of action. NO production was assayed by 
measuring the accumulation of nitrite in culture supernatants. They reported that 
Kaempferol inhibited NO production and iNOS protein expression 
in P. intermedia LPS-stimulated RAW264.7 cells at the translational level via HO-1-
mediated ROS reduction and could be an efficient modulator of host response in the 
treatment of periodontal disease. 
F.G. Amorim et al. (2012)
78
  investigated the role of G894T polymorphism in 
the eNOS gene as a predisposing factor to periodontal disease. They observed that the 
GG geno-type was associated with the progression of periodontal disease as indicated 
by an increase in frequency of approximately 18% in the moderate and 26% in the 
severe groups compared to the Healthy control group. Their finding indicated that 
patients carrying the GG genotype have a greater chance of developing periodontal 
disease compared with those carrying the T allele, and it reinforces the notion that 
genetic factors contribute to the development and aggravation of periodontal disease. 
F.S. Mariano et al. (2012)
79 
compared the production of antimicrobial 
peptides (s LL-37, human neutrophil peptides (HNP) 1-3) and NO by LPS-stimulated 
neutrophils isolated from healthy subjects and from patients with periodontitis. 
Peripheral blood neutrophils were cultured with or without Aggregatibacter 
actinomycetemcomitans-LPS (Aa-LPS),  Porphyromonas gingivalis-LPS (Pg-LPS)  
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and Escherichia coli-LPS (Ec-LPS). qRT-PCR was used to determine quantities of 
HNP 1-3 and LL-37 mRNA in neutrophils. Amounts of HNP 1-3 and LL-37 proteins 
in the cell culture supernatants were also determined by ELISA. NO levels in 
neutrophil culture supernatants were quantitated by the Griess reaction. Neutrophils 
from periodontitis patients cultured with  Aa-LPS, Pg-LPS and Ec-LPS expressed 
higher HNP 1-3 mRNA than neutrophils from healthy subjects. LL-37 mRNA 
expression was higher in neutrophils from patients stimulated with Aa-LPS. 
Neutrophils from periodontitis patients produced significantly higher LL-37 protein 
levels than neutrophils from healthy subjects when stimulated with Pg-LPS and Ec-
LPS, but no difference was observed in HNP 1-3 production. Neutrophils from 
periodontitis patients cultured or not with Pg-LPS and Ec-LPS produced significantly 
lower NO levels than neutrophils from healthy subjects. The significant differences in 
the production of LL-37 and NO between neutrophils from healthy and periodontitis 
subjects indicate that production of these molecules might influence individual 
susceptibility to important periodontal pathogens. 
 Very few studies have shown the influence of levels of NO on subjects with 
both periodontal disease and diabetes mellitus.
30, 73 
 
Nitric oxide and other oral diseases 
Liu R.H. et al.  (1995)
80
 found that salivary nitrite (implying that NO had 
been produced) was significantly increased in patients with OLP (Oral lichen planus) 
compared to healthy controls. It is clearly not possible to speculate whether salivary 
NO production was increased as a result of OLP, or whether increased salivary NO 
has a detrimental effect on the oral mucosa, and might be responsible in part for the 
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development of OLP. Increased salivary nitrite has also been found in patients with 
recurrent oral apthous ulceration. These findings suggest that excessive salivary NO 
has a potential role in modifying oral mucosal diseases as a patho-physiological 
regulator. 
Bentz et al. (1999)
81
 assessed NOS3 expression in a variety of benign and 
malignant salivary tumours and found increased NOS3 expression in all 48 tumours 
studied relative to normal salivary tissue where little NOS3 was found outside blood 
vessel endothelium.  
Brennan P.A. et al.  (2000)
82
 found that NOS2 was expressed both in 
pleomorphic adenoma and normal salivary ducts, and postulated that its expression in 
this tumour was due to its origin from myoepithelial cells. 
J.B. Patel et al.  (2009)
83
 evaluated nitric oxide and antioxidant enzyme levels 
in healthy individual without tobacco habits ,healthy individuals with tobacco habits, 
patients with oral precancers and oral cancer patients. They found that  plasma NO 2
-
 +NO 3
-
 levels were elevated in patients with oral precancers and oral cancer patients. 
The erythrocyte SOD and catalase activities were lower in oral cancer patients than 
patients with oral precancers. But erythrocyte SOD activity was higher in advanced 
oral cancer than the early disease.  They concluded that the alterations in antioxidant 
activities were associated with production of nitric oxide in oral cancer, which may 
have significant role in oral carcinogenesis. 
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Nitric oxide and other systemic diseases 
Nitric oxide is an important gas molecule that plays pivotal role in physiology 
and pathology in various systems. There is a large body of evidence that NO is 
involved in several inflammatory disorders. 
1) In vitro studies 
Sancak B. et al.  (2003)
84
 investigated the role of NO in Behcet’s disease. 
Behcet’s disease (BD) is a chronic multisystemic disorder which is characterized by a 
relapsing systemic inflammatory process. They measured serum nitrate + nitrite 
levels, by using an enzymatic one-step methodology based on the reduction of nitrate 
to nitrite by nitrate reductase from Aspergillus species, in the presence of beta-
NADPH. When compared to healthy controls, serum nitrate + nitrite levels were 
found to be higher in active periods of Behcet’s disease patients. It was concluded that 
increased NO production in patients with BD might have critical biological activities 
relevant to vasculitic events in the active period of disease. 
2) Animal studies  
K. E. Armour et al.  (1999)
85
 investigated the pathogenic role of NO in an 
animal model of inflammation-induced osteoporosis (IMO). NO production was 
increased in IMO when compared with controls, and this was accompanied by 
activation of inducible NOS (iNOS) in the bone marrow space. Bone mineral density 
(BMD) was reduced in IMO when compared with controls ,and this was found to be 
associated with reduced osteoblast numbers and increased osteoclast numbers . The 
NOS inhibitor L-NMMA reversed the deleterious effects of IMO on bone mass and 
bone turnover, but L-NMMA had no effect on bone mass in control animals. They 
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suggested that iNOS activation and increased NO production contribute to the 
pathogenesis of osteoporosis in these situations, but that NOS inhibitors could be of 
therapeutic value in the prevention and treatment of such bone loss. 
K. J. Armour et al. (2001)
86
 investigated the role of the inducible NO 
synthase (iNOS) pathway in the pathogenesis of inflammation-mediated osteoporosis 
(IMO) by studying mice with targeted inactivation of the iNOS gene iNOS knockout 
(iNOS KO) mice. IMO was induced in wild-type (WT) and iNOS KO mice by 
subcutaneous injections of magnesium silicate. The skeletal response was assessed at 
the tibial metaphysis by measurements of bone mineral density (BMD), using 
peripheral quantitative computed tomography, by bone histomorphometry, and by 
measurements of bone cell apoptosis. NO production increased 2.5-fold in WT mice 
with IMO, but did not change significantly in iNOS KO mice. Total BMD values 
decreased by a mean SEM of 14.4 ± 2.0% in WT mice with IMO, compared with a 
decrease of 8.6 ± 1.2% in iNOS KO mice with IMO. Trabecular bone volume was 
lower in WT mice with IMO and showed that IMO was associated with reduced bone 
formation and a 320% increase in osteoblast apoptosis in WT mice. iNOS KO mice 
with IMO showed less inhibition of bone formation than WT mice and showed no 
significant increase in osteoblast apoptosis. 
Pilichos et al.  (2004)
87
 assessed N
ω
-nitro-L-arginine
 
methyl ester (L-NAME) 
and aminoguanidine (AMG), the most
 
studied inhibitors of nitric oxide synthases, 
with regard to their
 
effectiveness as modulators of inflammation in trinitrobenzene
 
sulfonic acid (TNBS)-induced colitis in the rat. Over expression of nitric oxide (NO) 
has been implicated in the pathogenesis of experimental and clinical inflammatory 
bowel disease. They reported that administration of both nitric oxide synthases 
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inhibitors L-NAME and AMG were beneficial in all the examined parameters 
(clinical (body weight), haematological (hematocrit and erythrocytes sedimentation 
rate-ESR) and morphological (gross and microscopic) criteria ) compared with the 
control group. They concluded that NOS inhibitors might be promising agents in 
preventing the onset, or mediating the symptoms, of inflammatory bowel disease. 
3) Human studies 
N. Valero et al.  (2002)
88
 carried out a study in dengue fever patients. Dengue 
sera were taken 1 to 8 days after onset of the disease. Virus dengue is capable of 
inducing increased levels of NO when cocultured with human Kupffer and spleen 
cells. Because platelets can generate NO through stimulation of NO synthase, they  
performed experiments to determine the production of NO after coculture of human 
platelets with active and inactive forms of dengue virus type 2. Virus-platelet 
interaction did not contribute to increased levels of NO in the culture supernatants. 
They suggested that platelets are not a source of NO during the course of DF. Levels 
of NO in the severe form of illness (DHF) were not found to be increased; they were 
similar to the normal serum levels. Hence NO could play a role in the course of the 
disease. 
Y. Ersoy et al. (2002)
89
 conducted a study to assess and compare serum 
nitrate and nitrite levels in patients with ankylosing spondylitis, rheumatoid arthritis, 
and osteoarthritis. Concentrations of nitrate and nitrite in serum were determined by 
direct and indirect Griess reactions. C reactive protein and erythrocyte sedimentation 
rate levels were determined as markers of systemic activity of disease (SAD) in 
rheumatoid arthritis and ankylosing spondylitis groups. Their findings suggested that 
nitrate and nitrite production is enhanced in patients with inflammatory arthritis 
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compared with osteoarthritis. Serum nitrate and nitrite levels were enhanced in 
patients with rheumatoid arthritis, ankylosing spondylitis, and osteoarthritis compared 
with healthy subjects. A correlation was found between the SAD variables and serum 
nitrate and nitrite levels in patients with RA and AS. 
J. Brice Weinberg et al. (2006)
90
  assessed NO production in RA patients and 
compared levels of serum, urine, and salivary nitrite and nitrate (NOx) in patients 
with RA and normal subjects, and they examined the relationships of these measures 
to disease activity.  They found that RA patients had lower renal NOx clearance and 
lower renal NOx fractional excretion. 
Taffi R. et al. (2008)
91
 investigated changes in nitric oxide metabolism and 
oxidative stress status by measuring plasma nitric oxide (NO) and peroxynitrite 
(ONOO (-)) levels. Findings show that changes in NO metabolism may be considered 
as markers of brain injury in patients with ischemic stroke. 
A. Kulkarni et al. (2008)
92
 reported that serum nitric oxide and protein 
carbonyl levels were concomitantly increased and positively correlated with each 
other in patients with pulmonary tuberculosis  and extra-pulmonary tuberculosis. The 
changes in the level of nitric oxide and protein carbonyl are a reflection of increased 
defence mechanism and free radical activity in tuberculosis.  
Oates et al. (2008)
93
 demonstrated longitudinal associations between serum 
nitric oxide levels and markers of systemic lupus erythematosus and lupus nephritis 
disease activity. They found that NOx levels were associated with serum levels of C3 
and creatinine and the urinary protein, creatinine ratio. Among patients with lupus 
nephritis, those with proliferative lesions had higher NOx levels, and higher NOx 
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levels were associated with accumulation of renal damage and lack of response to 
therapy. 
Wimalawansa S.J. (2008)
94
 suggested that postmenopausal NO deficiency 
could be rectified with hormone replacement therapy, which enhance local production 
of NO. Declining local NO production secondary to estrogen deficiency in 
postmenopausal women, and perhaps in older men, could be one of the key reasons 
for age-related increased incidences of cardiovascular events, sexual dysfunction as 
well as osteoporosis. Thus, in addition to supplementation of NO compounds in acute 
situations such as alleviating angina and erectile dysfunction, it could be a valuable 
addition to the armamentarium of therapies for chronic conditions such as 
osteoporosis 
P. Hussain et al. (2008)
95
 used a genetic strategy to test the hypothesis that an 
inflammatory microenvironment with an enhanced level of NO. accelerates 
spontaneous tumor development. C. parvum– induced inflammation and increased 
NOS2 expression coincided with accelerated spontaneous tumor development, mostly 
lymphomas, in p53_/_NOS2+/+ C57BL6 mice when compared with the controls. In 
C. parvum–treated p53_/_NOS2+/+ mice, tumor development was preceded by a 
higher expression of NOS2 and phosphorylated Akt-Ser
 473
 (pAkt-Ser473) in spleen, 
increased cell proliferation measured by Ki-67 IHC in spleen and thymus, and a lower 
apoptotic index and CD95-L expression in spleen and thymus. C. parvum–treated 
p53_/_NOS2+/+ mice showed an increase in the number of Foxp3(+) T-reg cells, 
dendritic cells (DC), as well as increased CD80+, CD86+, CD40+, and CD83+ on DC 
in the spleen. Regulatory T-cells (T-reg) and the maturation of DCma y modulate 
tumorigenesis. An increase in the FoxP3 (+)T-reg cells in C. parvum–treated 
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p53_/_NOS2+/+ mice indicates a role of NO. in the regulation of T-reg cells that may 
contribute to a protumor shift of the immune environment favoring an accelerated 
tumor development. These data provided genetic and mechanistic evidence that an 
inflammatory microenvironment and an increased level of NO can accelerate tumor 
development. 
 Kumar et al. (2009)
96
 have studied NO levels of patients with ankylosing 
spondylitis (AS) using nitrite as a surrogate marker for NO. Levels of patients with 
ankylosing spondylitis were significantly higher than that of controls. Only one 
patient had levels comparable to those of controls. However, clinical assessment of 
disease activity , individual Assessment in Ankylosing Spondylitis domains-physical 
function (BASFI), pain, patient global assessment and inflammation did not show a 
good correlation with serum nitrite levels. 
B. Bayram et al. (2009)
97
 investigated plasma nitric oxide synthesis activity 
at acute phase of stroke and stroke subtypes. The plasma nitric oxide synthesis 
activity was determined by colorimetric assay in conformity with the kit procedure. 
Plasma nitrite+nitrate levels were determined as 0.83 (0.83-0.83) μM and 0.89 (0.76-
1.12) μM for the patient group and the control group respectively. They asserted that 
plasma nitric oxide synthesis activity does not constitute an important criterion for 
stroke and stroke subtypes. 
E. M. Mahdy et al. (2011)
98
 reported that serum determination of HGF, Bcl-2 
or NO may help in diagnosis of the breast cancer and may aid in disease prognosis. 
They suggested that elevated nitrate and nitrite levels in the patients may be a result of 
increased NOS II activity, which is stimulated by a host defense system against tumor 
growth. NO might  promote tumor growth by modulating the production of 
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prostaglandins and activate cyclooxygenase-2 (COX-2), by generating prostaglandins, 
promotes angiogenesis and inhibits apoptosis.  
M. Miletic et al. (2012)
99
 tested the serum levels of IL-17 and nitric oxide (as 
possible IL-17-induced product), in  patients with primary Sjogren’s syndrome , an 
intricate and complex chronic autoimmune disorder of exocrine glands and suggested 
that  they have  increased IL-17 and NO  production, especially if they had associated 
elevated rheumatoid factor and antinuclear antibody values. 
P. Samant et al. (2012)
100
 performed a study to determine whether 
hyperuricemia depletes serum NO level in diabetic patients and to find out correlation 
between the levels of NO in study group. The elevated level of uric acid is a risk 
factor in diabetes mellitus. Hyperuricemia if not corrected can inactivate NO which 
leads to hyperlipidemia & increases the risk of cardiac diseases by affecting 
endothelial function & arterial stiffness. The values of fasting sugar, lipid profile, and 
serum uric acid were estimated by auto analyzer using transasia kits. Serum NO was 
estimated by Cortas & Wakid method. Diabetic patients with hyperlipidemia & 
hyperuricemia showed highly significant decreased levels of serum NO. Their results 
suggest that diabetic patients with hyperlipidemia & hyperuricemia shows low levels 
of serum NO & indicate that hyperuricemia inactivates serum NO and decreases its 
bioavailability. 
E. Profumo et al. (2012)
101
 investigated a possible association of oxidized 
low-density lipoproteins (ox-LDLs), nitric oxide (NO), 3-nitrotyrosine, vitamin A, 
vitamin E, and β-carotene serum levels with subclinical atherosclerosis in rheumatoid 
arthritis and psoriatic arthritis. By the use of ELISA, they observed higher ox-LDL 
levels in patients with intima-media thickness (IMT) > 1 than in patients with         
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IMT ≤ 1 and a negative correlation between NO levels and IMT values. By the use of 
high-performance liquid chromatography, we determined higher levels of vitamin A 
in patients with psoriatic arthritis and IMT ≤ 1 than in controls and lower levels of β-
carotene in patients with rheumatoid arthritis and psoriatic arthritis than in controls. 
They confirmed that ox-LDLs and NO may be markers of accelerated atherosclerosis 
in rheumatoid arthritis and psoriatic arthritis. 
 
 
   
 
Materials & Methods 
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The subjects in this study were selected from the outpatients at the department 
of Periodontics, Sree Mookambika Institute of Dental Sciences, Kulasekharam, from 
September 2012 to December 2012. Subjects who fulfilled the following 
inclusion/exclusion criteria were included in the study. 
Inclusion criteria 
 Age group: 20-70 years 
 Subjects with a diagnosis of chronic generalized  periodontitis based on 
the clinical criteria proposed by the 1999 world workshop for classification 
of periodontal diseases and conditions.
102
 Patients diagnosed with chronic 
periodontitis should have atleast 15 natural teeth, more than 30%sites with 
clinical attachment loss ≥4mm  and probing pocket depth ≥ 5mm at 
baseline.  
 Well-controlled  type 2 diabetes mellitus patients were selected and 
classified based on criteria given by American Diabetic Association in 
2008 and HbA1c levels ≤7% .73 
 Healthy subjects without chronic periodontitis and other systemic diseases 
as control group. 
 Subjects who have not received periodontal therapy within the last 6 
months.  
 Exclusion criteria 
 Subjects with any other systemic disease (except type2 diabetes) 
 Subjects who have used anti-inflammatory drugs or antimicrobial drugs 
within a 3 month period before the study began 
 Subjects who have used mouthwashes within previous 3 months 
Materials and Methods 
 
39 
 
 Subjects who have used vitamin supplements within previous 3 months 
 Pregnant or lactating females 
 Subjects who are smokers or alcoholics 
 Subjects who have special dietary requirements 
Informed consent was obtained from all subjects after the screening. Before obtaining 
consent , information on the the nature and  potential benefits of their participation in 
the study, was also explained. The study protocol was approved by Ethics Committee 
of Sree Mookambika Institute of Medical Sciences, Kulasekharam. 
The selected patients were assigned into 3 groups; each group consist of 30  patients:  
Group I Healthy subjects without chronic periodontitis and other systemic 
diseases 
Group II Chronic periodontitis patients 
Group III Patients with chronic periodontitis and type2 diabetes mellitus (Well 
controlled – HbA1c levels ≤ 7%) 
Clinical parameters 
Periodontal examination was conducted at the department of Periodontics, 
Sree Mookambika Institute of Dental Sciences, Kulasekharam. All investigations 
were performed by single examiner. 
The following clinical parameters were assessed at six sites of all teeth                       
(Mesiobuccal, mid- buccal, disto buccal, mesio-lingual, mid lingual and disto-lingual) 
using William’s graduated periodontal probe. Clinical parameters were assessed at 
baseline and 4 weeks after initial periodontal therapy. [Refer colorplate. 1 & 2]  
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Initial periodontal therapy includes oral hygiene instructions and full mouth 
subgingival scaling. 
1. Oral Hygiene- Simplified Index(OHI-S) –Greene and Vermillion – 1964) 
2. Gingival Index (GI)- Loe and Silness-1964) 
3. Probing pocket depth (PPD) 
4. Clinical attachment level (CAL) 
Collection of sample 
A fasting blood sample (5ml of venous blood) was collected from the 
antecubital fossa by venipuncture using a 20 guage needle with 5ml syringe, before 
periodontal examination at baseline and 4 weeks after initial periodontal therapy. 
[Refer colorplate.  3a & 3b] Serum was separated from blood by centrifuging the 
sample at 3000xg for 10 min. and stored till the assay procedures. [Refer colorplate. 
4&5] 
Biochemical assay 
NO is a highly reactive free radical gas and remains stored in tissues as 
nitrates (NO3
-
) or nitrites (NO2
-
). Thus , NO concentration can be estimated  by 
measuring concentrations of nitrates (NO3
-
) and  nitrites (NO2
-
) in  combination.
23
 The 
reduction of nitrate to nitrite by copper coated cadmium granules followed by Griess 
colorimetric reaction can be used to measure the nitrite levels (NO2
-
)
28,103
.All the 
reagents used in this study were of analytical grade. 
Reagents 
1. Cadmium granules-  Cadmium granules are obtained from Fluka Chemische 
Fabrik AG, Buchs Switzerland. Using a wire cutter,  cadmium granules are 
Materials and Methods 
 
41 
 
broken down into smaller pieces (20 to 40 mg) and  stored in 0.1 mol/L H2S04, 
they are stable for at least nine months. [Refer colorplate.6] 
2. Glycine-NaOH buffer-  It is prepared by dissolving 15.0 g of glycine (Sigma 
Chemical Co., St. LOUIS, MO) in de-ionized distilled water, adjust pH to 9.7 
with 2 mol/L NaOH solution, and make up to 1 L.  
3. Sulfanilamide- It is prepared by dissolving 5 g of sulphanilamide in 500 mL of 
warm 3 mol/L HCI solution, then let cool. This is stable for one year at room 
temperature. 
4. N-Naphthylethylene diamine- It is prepared by dissolving 50mg of N-
Naphthylethylene diamine in 250mL of distilled water. This is stable for two 
months at 0 to8⁰C. 
5. Standards- Working standards are prepared by diluting stock 0.1mol/L 
solutions of NaNO2 or KNO3 on the day of use. Working standards are stable 
for three days. 
Methods 
Activation of cadmium granules:   
Rinse the acid from the granules three times with de-ionized distilled water. 
[Refer color plate.7] Swirl the granules for 1 to 2 minutes in a 5 mmol/L CuSO4 
solution in glycine-NaOH buffer. [Refer colorplate. 8]  Drain, and then rinse the 
CuS04 three times with glycine buffer. Drain and use the copper-coated granules 
within 10 minutes. [Refer colorplate.9] Prolonged exposure of the granules to air 
diminishes their reductive ability. After use, rinse the granules and store them in 0.1 
mol/L H2SO4 solution. 
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Deproteinization of sample: 
 Add 0.5ml of serum to 2.0ml of 75mmol/L zinc sulphate (ZnSO4) solution. 
Then add, with mixing, 2.5ml of 55mmol/L NaOH reagent. The final pH should be 
between 7.0 and 7.5. [Refer colorplate.10]  Let stand for 10 minutes. From this after 
centrifugation 1 ml supernatant taken for nitrite estimation. 
Nitrite assay: 
 Label test tubes - blank, sample and standard. Add 1ml of glycine-NaOH 
buffer to each. Then add 1ml of the clear supernatant of the deproteinized sample into 
the sample tubes. Adjust the volume in all the test tubes to 4ml by adding de-ionized 
distilled water.  
 Blank Sample Standard 
Glycine- NaOH buffer 1ml 1ml 1ml 
Deproteinized sample - 1ml - 
Working standard - - 3ml 
Distilled water 3ml 2ml - 
 
Start the reaction by adding 2.5 to 3gm of freshly activated cadmium granules and stir 
once by swirling. Exactly 90 minutes later transfer 2.0ml from each test tube to an 
appropriately labelled test tube for nitrite determination. Add 0.5ml of distilled water 
to all tubes to yield a volume of 2.5ml. . Then add 1ml of sulphanilamide solution, 
followed by 1ml of N- naphthylethylenediamine. Mix well. [Refer colorplate.11]  
Take sample in a cuvette.[Refer colorplate. 12] Then read absorbances at 545 nm 
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after 20-60 minutes using a spectrophotometer [Refer colorplate. 13] , against the 
blank containing reagents but no biological sample.  
Formula for measurement of nitrite levels 
OD of sample × Concentration of standard (µg)                                                                        
  × total volume (ml) × 1000 * ml 
--------------------------------------------------------------- = Concentration of sample(µg) 
OD of standard × 1 ml supernatant  × 0.5 ml serum 
 
 Molecular weight of NO2 = 46 
   Therefore,       Concentration of sample ( µg) 
   ------------------------------------          = Level of nitrite (µM/L) 
                    46 
 
OD - Optical density  
1000* = Multiplying with 1000 is for calculating the NO2 value to litre of serum  
so, final value is in micromol/ litre (µM/L) 
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The purpose of this study was to compare the serum levels of NO before and 
after initial periodontal therapy in healthy and chronic periodontitis with and without 
Type II Diabetes Mellitus patients. This study included a total number of 90 patients 
of both sexes  and satisfying the inclusion criteria. The patients were categorized into 
3 groups of 30 patients each: 
Group I Healthy subjects without chronic periodontitis and other systemic 
diseases 
Group II Chronic periodontitis patients 
Group III Patients with chronic periodontitis and type2 diabetes mellitus 
 
Baseline data for OHI-S, GI , PPD, CAL were recorded for all the patients in each 
group. Venous blood was collected from all the patients in each group to estimate the 
serum levels of  NO. Serum nitrite levels were estimated by Spectrophotometric 
method using the Griess colorimetric reaction.  After initial periodontal therapy, at the 
end of 4 weeks all the periodontal parameters were recorded and serum levels of NO 
was estimated.  
 
Statistical analysis  
             The data was analysed by a software SPSS (version 16.0). Paired t test was 
used for statistical significance within the group comparison (pre and post treatment). 
ANOVA was used for multiple comparisons between groups. Post Hoc Test followed 
by Dunnet t test was applied to find the statistical significance at 95% confidence 
interval. P < 0.05 considered statistically significant. 
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Interpretation of results 
 
Table. 1: Demographic characteristics of the study population 
 
Groups Gender Number of subjects in different age groups 
Male Female 21-30 Y 31-40 Y 41-50 Y 51-60 Y 61-70 
Y 
Group-I 13 17 27 3 0 0 0 
Group-II 13 17 0 9 12 7 2 
Group-III 22 8
 
0 7
 
8
 
12 3
 
 
 Group I consisted of 13 males and 17 females with maximum number of 
subjects between 21-30 years of age group. Group II consisted of 13 males and 17 
females with maximum number of subjects between 41-50 years of age group. Group 
III consisted of 22 males and 8 females with maximum number of subjects between 
51 and 60 years of age group. 
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Table. 2 & 3 shows the mean values of pre–treatment and post treatment periodontal 
parameters and serum levels of NO of the 3 groups.   
 
Table. 2 : Pre treatment 
Groups OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD  (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L) 
(Mean±SD) 
Group-I 1.95±0.52 1.09±0.46 1.85±0.19 1.85±0.18 65.23±1.57 
Group-II 3.64±0.53 1.93±0.30 3.29±0.42 3.60±0.42 89.21±1.46 
Group-III 3.66±0.44 2.03±1.32 3.57±0.40 3.65±0.45 85.54±1.54 
 
 
Table. 3: Post treatment 
Groups OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L)  
(Mean±SD) 
Group-I 0.72±0.27 0.24±0.15 1.76±0.22 1.76±0.18 56.29±1.24 
Group-II 1.73±0.42 1.27±0.23 3.16±0.46 3.47±0.58 70.91±1.68 
Group-III 2.39±0.49 1.71±0.33 3.44±0.42 3.61±0.48 68.69±1.17 
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Table. 4: Comparison of pre and post treatment periodontal parameters and 
serum levels of nitric oxide in group-I 
 
Treatment OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL  (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L) 
(Mean±SD) 
Pre- 
treatment 
1.95±0.52 1.09±0.46 1.85±0.19 1.85±0.18 65.23±1.57 
Post-
treatment 
0.72±0.27* 0.24±0.15* 1.76±0.22 1.76±0.18 56.29±1.24* 
(*P<0.05 significant compared pre-treatment with post treatment) 
 
         At the start of the trial, the mean value for  OHI-S  was 1.95±0.52. At the end of 
4 weeks following therapy the mean value for OHI–S  was reduced to 0.72±0.27 
which was significant statistically (p < 0.05). 
          The   mean value for  Gingival index  showed a decrease from the initial mean 
value of 1.09±0.46   to 0.24±0.15 which was significant statistically (p < 0.05). 
         The probing pocket depth showed an initial mean value of 1.85±0.19mm. At the 
end of  4 weeks it reduced to 1.76±0.22mm which was not significant statistically. 
          The   mean value for  CAL   showed a decrease from the initial mean value of 
1.85±0.18mm  to 1.76±0.18mm which was not  significant statistically. 
        The mean value of serum levels of NO at baseline was 65.23±1.57μM/L and it 
was reduced to 56.29±1.24 μM/L at the end of 4 weeks which was significant 
statistically (p < 0.05). 
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Table. 5: Comparison of pre and post treatment periodontal parameters and 
serum levels of nitric oxide in group-II 
Treatment OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric 
oxide 
(µM/L)  
(Mean±SD) 
Pre- 
treatment 
3.64±0.53 1.93±0.30 3.29±0.42 3.60±0.42 89.21±1.46 
Post-
treatment 
1.73±0.42* 1.27±0.23 3.16±0.46 3.47±0.58 70.91±1.68
* 
 (*P<0.05 significant compared pre-treatment with post treatment) 
 
            The OHI-S scores  showed an initial mean value of 3.64±0.53. At the end of  4 
weeks it reduced to 1.73±0.42 which was  significant statistically ( p < 0.05).  
The   mean value for  gingival index  showed a decrease from the initial mean 
value of 1.93±0.30   to 1.27±0.23 which was  not significant statistically. 
       There was no much reduction in the  probing pocket depth  from the  initial 
mean value of 3.29±0.42mm to  3.16±0.46mm which was not significant statistically. 
        The   mean value for  CAL   showed a decrease from the initial mean value of 
3.60±0.42mm to 3.47±0.58mm which was not  significant statistically. 
         The mean value of serum levels of NO at baseline was 89.21±1.46 μM/L and 
it  reduced to 70.91±1.68 μM/L at the end of 4 weeks which was significant 
statistically(p < 0.05). 
 
 
 
 
 
Results and Observations 
 
 49 
 
Table. 6: Comparison of pre and post treatment periodontal parameters and 
serum levels of nitric oxide in group-III 
Treatment OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L)  
(Mean±SD) 
Pre- 
treatment 
3.66±0.44 2.03±1.32 3.57±0.40 3.65±0.45 85.54±1.54 
Post-
treatment 
2.39±0.49* 1.71±0.33 3.44±0.42 3.61±0.48 68.69±1.17* 
(*P<0.05 significant compared pre-treatment with post treatment) 
 
            At the start of the trial the mean value for  OHI-S  was 3.66±0.44   . At the 
end of 4 weeks following therapy the mean value for OHI–S  reduced to 2.39±0.49 
which was significant statistically (p < 0.05). 
          The   mean value for  gingival index  showed a decrease from the initial mean 
value of 2.03±1.32   to 1.71±0.33 which was  not statistically significant. 
         The probing pocket depth showed an initial mean value of 3.57±0.40mm . At 
the end of  4 weeks it reduced to 3.44±0.42mm which was not significant statistically.     
  There was no much reduction in the  CAL   from the  initial mean value of 
3.65±0.45mm to  3.61±0.48mm which was not significant statistically. 
               The mean value of serum levels of NO at baseline was 85.54±1.54 μM/L 
and it  reduced to 68.69±1.17 μM/L at the end of 4 weeks which was significant 
statistically(p < 0.05). 
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Table. 7: Comparison of pre treatment periodontal parameters and serum levels 
of nitric oxide between groups 
Groups OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L)  
(Mean±SD) 
Group-I 1.95±0.52 1.09±0.46 1.85±0.19 1.85±0.18 65.23±1.57 
Group-II 3.64±0.53* 1.93±0.30* 3.29±0.42* 3.60±0.42* 89.21±1.46* 
Group-III 3.66±0.44* 2.03±1.32*
,# 
3.57±0.40* 3.65±0.45* 85.54±1.54* 
(*P<0.05 significant compared group-I with other groups, 
#
 P<0.05 significant 
compared group-II with other groups) 
       
The mean value of OHI-S scores of group II and group III was markedly higher when 
compared to group I  which was significant statistically. However, no statistically 
significant difference was observed between group II& III.  
          When the  mean value of  GI scores  of  the 3 groups was compared, group II 
and group III showed  higher  values when compared to group I  which was 
statistically significant.     Similarly a statistically significant difference was observed 
when group II& III were compared  (p < 0.05).  
      The  mean value of probing pocket depth  of group II and group III were 
markedly higher when compared to group I  which was significant statistically. 
However, when group II& III  were compared,  no statistically significant difference 
was observed.    
          When   the  mean values of CAL  of group II and group III were compared 
with group I , higher  mean values was observed with respect to group II &III which 
was significant statistically. However, comparison between group II& III showed no 
statistically significant difference.  
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 When comparison of the mean value of serum levels of NO at baseline for 3 
groups  was done ,  higher values was observed for group II & III when compared to 
group I which was statistically significant . However when the values of group II &III 
were compared it was not significant statistically.  
 
Table. 8: Comparison of post treatment periodontal parameters and serum levels 
of nitric oxide between groups 
Groups OHI-S 
(Mean±SD) 
Gingival 
Index 
(Mean±SD) 
PPD (mm) 
(Mean±SD) 
CAL (mm) 
(Mean±SD) 
Nitric oxide 
(µM/L) 
(Mean±SD) 
Group-I 0.72±0.27 0.24±0.15 1.76±0.22 1.76±0.18 56.29±1.24 
Group-II 1.73±0.4* 1.27±0.23* 3.16±0.46* 3.47±0.58* 70.91±1.68* 
Group-III 2.39±0.49*
# 
1.71±0.33*
,# 
3.44±0.42* 3.61±0.48* 68.69±1.17*
# 
(*P<0.05 significant compared group-I with other groups, 
#
 P<0.05 significant 
compared group-II with other groups) 
 
        The mean value of OHI-S scores of group II and group III was markedly higher 
when compared to group I which was significant statistically. However, a statistically 
significant difference was observed when comparison between group II& III  was 
done (p < 0.05). 
          When the  mean value of  GI scores  of  the 3 groups was compared, group II 
and group III showed  higher  values when compared to group I  which was 
statistically significant. When comparison between group II& III  was done, a 
statistically significant difference was observed (p < 0.05) . 
      The mean value of probing pocket depth of group II and group III was 
markedly higher when compared to group I  which was significant statistically. 
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However, comparison between group II& III  showed no statistically significant 
difference.    
         When   the  mean values of CAL  of group II and group III was compared with 
group I , higher  mean values was observed with respect to group II &III which was 
significant statistically . However, no statistically significant difference was observed 
when comparison between group II& III  was done. 
        When comparison of the  mean value of serum levels of NO  for 3 groups  was 
done ,  higher values was observed for group II & III when compared to group I 
which was statistically significant . However, a statistically significant difference was 
observed when comparison between group II& III  was done ( p < 0.05).  
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Graph. 1: Demographic data of number of male and female in different groups 
 
 
 
 
Graph-2: Demographic data of the subjects in different age groups 
 
 
  
 
Graph-3: Comparison of pretreatment and post treatment Oral hygiene index- 
simplified (OHI-S) values  
 
 
 
Graph-4: Comparison of pretreatment and post treatment Gingival Index (GI) values 
 
 
  
 
Grpah-5: Comparison of pretreatment and post treatment Probing Pocket Depth (PPD) 
values in (mm) 
 
 
 
Graph-6: Comparison of pre treatment and post treatment clinical attachment level 
(CAL) values in (mm) 
 
  
 
Graph-7: Comparison of pre treatment and post treatment serum level of nitric oxide 
(NO) values in (µM/L) 
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Diabetes mellitus and periodontal disease are common chronic diseases that 
have long been considered to be biologically linked that contribute to each other’s 
severity and worsen each other’s prognosis. A plethora of epidemiologic studies have 
demonstrated that periodontitis is more prevalent in type I and type II diabetes 
mellitus compared to non-diabetics.
104
 The incidence of periodontal disease increased 
by nearly threefold in patients with type 2 diabetes as compared to type 1 diabetes 
mellitus. The odd’s ratio for periodontal disease among subjects with type2 diabetes 
mellitus ranges from 2to 4.
105,106,107
 In the present study, a total of 90 subjects were 
selected and categorized into 3 groups, each group comprising of  30 subjects - group 
I (Healthy controls), group II (chronic periodontitis) and group III (chronic 
periodontitis patients with type2 diabetes mellitus).  
Several studies investigated the relationship between diabetes mellitus and 
periodontitis clinically, outcomes were often controversial.
73,108,109,110,111
 Diagnostic 
parameters and methodologies are not universally defined, which makes comparison 
of the available evidence difficult
73
. In the present study, the periodontal parameters 
like OHI-S, GI, PPD and CAL values were higher in group III at baseline with mean 
values: 3.66±0.44, 2.03±1.32,3.57±0.40mm,3.65±0.45mm respectively as compared 
to group I and group II. At baseline, there was no significant difference for the 
periodontal parameters between patients in group II and group III except for GI with 
mean value of 2.03±1.32 (p˂0.05) in group III when compared to 1.93±0.30 in group 
II. This was in agreement with the study of Nowak et al
112
 where clinical parameters 
such as PI, GI, PD and CAL values were higher in patients with diabetes and 
periodontitis compared to patients with only chronic periodontitis. Several 
mechanisms have been proposed to explain the greater incidence and severity of 
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periodontal disease in patients with diabetes. These include polymorphonuclear 
leukocyte changes, deregulated cytokine dysfunction, vascular changes, altered 
collagen and glycosaminoglycans synthesis, and the formation of AGEs.
73
 AGEs form 
a critical link between numerous diabetic complications, because they induce marked 
changes in cells and extracellular matrix components. These changes, including 
abnormal endothelial cell function, capillary growth and vessel proliferation, also 
occur in the periodontium of some people with diabetes.
113
  AGEs with markers for 
increased oxidative stress have been demonstrated in human gingiva of subjects with 
chronic periodontitis and diabetes mellitus.
114
 It has been postulated that AGE-RAGE 
interaction induces an oxidant stress that may be responsible for monocytic 
upregulation, activation of NF-kB and subsequent expression of mRNA and secretion 
of proinflammatory cytokines such as IL-1β, TNF –α and IL-6by monocytic 
phagocytes involved in periodontal tissue inflammation and destruction.
115,116,117 
 Increasing evidences suggest that oxidative stress and changes in nitric oxide 
formation or action play a major role in chronic inflammatory diseases such as 
periodontitis and diabetes mellitus.
30
 In the present study we measured serum nitric 
oxide levels indirectly by estimating nitrite levels the stable end products of nitric 
oxide oxidation by Griess reaction. It has been reported that endogenous nitric oxide 
production is highly correlated with nitrate and nitrite levels in serum and plasma. 
28
 
Hence estimation of nitrite and nitrate is a relative measure of nitric oxide production 
in vivo. 
28,29
 
NO is a gaseous, free radical, which can readily diffuse through cytoplasm and 
plasma membrane due to its solubility in both aqueous and lipid environments.
44,118
  It 
has a short biological half life
44
.  NO is generated enzymatically from L- Arginine by 
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a family of nitric oxide synthase (NOS) isoforms.
44
 NO is a ubiquitous molecule 
essential for many biologic functions, namely neurotransmission
119
, vasodilation
24
, 
cytotoxicity
25
 and immuno regulation
26
, all of which are likely to be relevant to the 
pathogenesis of periodontal disease. In periodontitis lesion considerable quantities of 
NO may be generated, for prolonged duration, most likely by macrophages, PMNs, 
lymphocytes and fibroblasts following cytokines and LPS induction. 
120
 
 
The results of our study showed a higher value in the serum levels of NO in 
group II when compared to group III and group I with mean values 89.21±1.46 μM/L, 
85.54±1.54 μM/L, 65.23±1.57 μM/L respectively at baseline. This was in accordance 
to the previous study
23
 where increased NO levels were found in saliva and GCF of 
subjects with chronic periodontitis as compared to healthy subjects. Studies have 
shown that oral de novo  nitric oxide production increases during deposition of plaque 
which might be an early host defense mechanism against bacterial proliferation in 
plaque
 68
. NO is known to potentiate matrix degradation which includes suppression 
of proteoglycan and collagen synthesis
120, 121
 and upregulation of metalloproteinases 
activity.
 120,122
 
Elevated NO production in chronic periodontitis is a reflection of an immune- 
activated state on which inflammatory cytokines and other mediators are upregulated. 
Cytokine and bacterial toxin –induced NO upregulates IL-1, TNF-α and IL-8 
production by neutrophils a possible mechanism contributing to the escalation of 
inflammation in periodontal disease. 
120
 NO has been shown to directly activate both 
constitutive and inducible forms of cycloxygenase (COX) enzyme, leading to increase 
in  PGE2 production and enhances bone resorption in periodontal disease. 
76,123
  It was 
also reported that Th1 type cytokines increase the expression of  NOS and prime the 
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membrane bound NADPH oxidase of neutrophils and monocytes of mice leading to 
an activated state, which upon second stimulus releases upto six fold increased levels 
of ROS than do unprimed phagocytes and enhances tissue destruction. 
120
 In our study 
, lower value of serum NO levels were observed in group III when compared to group 
II  at baseline, which was statistically significant (p˂0.05). The possible underlying 
mechanism for the significant decrease in serum nitric oxide levels in patients with 
chronic periodontitis and diabetes mellitus in our study could be due to impaired 
circulation observed in diabetic patients which limits the availability of NOS and 
NO
124
. It has been reported that glycosylation of haemoglobin impairs the NO 
vasodilator function of RBC. Glycosylated haemoglobin binds NO in the form of 
nitrosothiols very tightly so that any NO that is formed cannot be easily released from 
RBC and aggravates the consequences of endothelial dysfunction in diabetes 
mellitus
124
. Moreover, there is evidence that AGEs can have an inhibitory action on 
NO. Several mechanisms by which AGEs reduce or block NO activity have been 
proposed.  AGEs reduce the half-life of endothelial NO synthase (eNOS) mRNA 
through an increased rate of mRNA degradation and reduced eNOS activity. Another 
mechanism proposes that AGEs impair NO production via the binding of CML (N
ε
-
(carboxymethyl) lysine- a stable AGE compound)  residues to endothelial AGE 
receptors, causing a reduction in phosphorylation of serine residues in eNOS, 
resulting in deactivation of the enzyme.
125
 
Studies have shown that hyperglycemia- -induced oxidative stress increases 
assymetrical dimethyl arginine (ADMA) , an endogenous inhibitor of NO synthesis, 
in type 2 diabetes mellitus. Oxidative stress can reduce the bioavailability of NO and 
activation of the polyol pathway, which increases the use of nicotinamide adenine 
dinucleotide phosphate can reduce the biosynthesis of NO.
57,126
 It has also  been 
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reported that the kidney dysfunction associated with diabetes mellitus may prevent the 
elimination of major NOS inhibitor, asymmetrical dimethyl arginine (ADMA) thereby 
limiting the production of NO in type 2 diabetes mellitus patients.
124
 
Our study was an interventional study in which all the clinical parameters and 
serum nitric oxide levels were re-estimated four weeks after initial periodontal 
therapy in all the three groups. Results showed a reduction in all the clinical 
parameters -OHI-S, GI,PPD,CAL- in all the three groups. However the reduction in 
OHI-S and GI values were statistically significant (p˂o.o5). This is in agreement with 
previous studies
127,128
 in which initial periodontal therapy was associated with 
improved periodontal health in type 2 diabetes mellitus patients. 
The serum nitric oxide levels in all the three groups  after initial periodontal 
therapy also showed a decline from its baseline values . We observed a statistically 
significant reduction in group II when compared to group III after initial periodontal 
therapy. However there is no evidence to support the influence of initial periodontal 
therapy in lowering the serum levels of NO in chronic periodontitis with or without 
type 2 diabetes mellitus. 
Currently an alternative approach to reduce periodontal inflammation using 
NOS inhibitors has been proposed. Selective inhibitors of iNOS - 
mercaptoethylguanidine, guanidoethyldisulfide, aminoguanidine- are shown to reduce 
peroxynitrite formation as well as inhibiting prostaglandin production via inhibition of 
COX.
37, 62,129
 It is therefore logical that modulation of this biological messenger might 
be useful for the treatment of chronic inflammatory diseases such as periodontal 
disease and diabetes mellitus.  
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There were several drawbacks in this study. 1) Age group included in the 
study ranged from 20-70 years. 2) Male to female ratio was not matched  3) Sample 
size selected for the study was small.  4) The initial periodontal therapy was limited to 
subgingival scaling alone and no root planing was performed.  
   
 
Summary & Conclusion 
 
Summary and Conclusion 
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Periodontal disease and diabetes mellitus are strongly interrelated and have 
common pathobiology. Inflammatory events during periodontal disease may play a 
important role on development of diabetes and insulin resistance probably facilitates 
the progress of periodontal disease. 
Indeed virtually every cell and many immunological parameters are modulated 
by nitric oxide. It has been shown that nitric oxide can have pro-inflammatory or anti-
inflammatory actions during infections. For these reasons nitric oxide has been 
described as ‘double edged sword mediator’. And this phenomenon is often referred 
to as nitric oxide paradox. Hence serum NO levels can be utilized as a good indicator 
of the inflammatory status of the periodontium and evaluating these levels in the 
serum by Spectrophotometric method using Griess reaction  is a reliable and faster 
method to estimate the level of inflammation in the periodontal tissues. 
However further studies need to be conducted as to whether the administration 
of some chemical inhibitors of NOS or antioxidants in addition to mechanical therapy 
can be of some help to modulate the host response in inflammatory periodontal 
diseases. 
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 APPENDICES 

 SREE MOOKAMBIKA INSTITUTE OF DENTAL SCIENCES, 
KULASEKHARAM – 629161 
Part-I 
PATIENT INFORMATION SHEET 
 
Study title: “A comparative study on serum levels of nitric oxide before and after 
initial periodontal therapy in healthy and type 2 diabetes mellitus patients with 
chronic periodontitis” 
You are being invited to take part in the above mentioned study. Before you decide it 
is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or 
not you wish to take part. 
1) What is the purpose of the study? 
 To assess the influence of nitric oxide in serum of healthy and type 2 diabetes 
mellitus patients with chronic periodontitis.  
 To find out the effect of initial periodontal therapy on the serum levels of 
nitric oxide in healthy and type 2 diabetes mellitus patients with chronic 
periodontitis. 
 
2) Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take 
part you will  be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. This will not affect the standard of care you 
receive. 
 
3) What will happen to me if I take part? 
The investigator will ask you few questions and will evaluate your oral 
hygiene status and periodontal health status. 5ml of venous blood will be 
 collected from the antecubital fossa by venipuncture before and 4 weeks after 
initial periodontal therapy for the assay. 
 
4) What are the risks of taking part? 
There are no risks in taking part this study. 
 
5) Will my taking part in this study be kept confidential? 
All information collected from you will be kept confidential. No personal 
details will be revealed to anyone. 
 
 
Contacts for Further Information 
Investigator 
Dr.Gayathri.S 
Mob: 08903247177  
Mail Id: gkathu@gmail.com 
 
Guide  
Dr. Elizabeth Koshi , MDS 
Mob: 09447154335 
Mail Id: elizabethkohi_dr@yahoo.com 
 
Co- guide 
Dr. Arun Sadasivan , MDS 
Mob: 09847246961 
Mail Id: sadasivan_arun@hotmail.com 
                              
       Thank you for taking part in this study. 



  
Part-II 
 
PATIENT CONSENT FORM 
 
 I hereby declare that I will comply with all the treatment procedures needed 
for  “A comparative study on serum levels of nitric oxide before and after initial 
periodontal therapy in healthy and type 2 diabetes patients with chronic periodontitis”, 
for which blood samples will be drawn before and four weeks after periodontal 
therapy. Doctor has explained to me all the procedures. I have had the opportunity to 
ask questions about it and any questions that I have asked have been answered to my 
satisfaction. I consent voluntarily to participate as a participant in this study and 
understand that I have the right to withdraw from the study at any time without in any 
way affecting my dental care. 
 
 
Doctor’s Name                       Patient’s Name 
 
  (Signature)           (Signature) 
 
 


 A comparative study on the serum levels of nitric oxide before and after initial 
periodontal therapy in healthy and type 2 diabetes mellitus patients with chronic 
periodontitis 
Patient record form (Pre- treatment) 
                                 GROUP I / GROUP II/ GROUP III 
Serial No:                                    Date: 
Name:           Age:                    Sex:  M / F 
Address:                         Occupation: 
 
Medical history: 
 
Drug history: 
 
CLINICAL PARAMETERS  
I. Oral Hygiene  Index – Simplified (Greene and Vermilion-1964) 
     Debris Index-S           Calculus Index-S 
 
 
 
 
 
Score:  
Interpretation: 
 
 
   
16 11 26 
46 31 36 
   
   
16 11 26 
46 31 36 
   
Good  Fair  Poor  
 II. Gingival Index (Loe and Silness-1963) 
 
 
 
 
 
 
 
 
 
 
Score:  
Interpretation: 
 
 
 
BLOOD INVESTIGATION 
 
Random blood sugar (RBS) / Glycated haemoglobin (HbA1c) level:  
 
NO level: 
 
 
         
   
16 12 24 
44 32 36 
   
         
Mild  Moderate  Severe  
  
PERIODONTAL STATUS 
MAXILLA 
 
 
 D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B 
 D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P 
 
Recession 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
Enlargement 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
PPD 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
CAL 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
  
PERIODONTAL STATUS 
MANDIBLE 
 
 D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B 
 D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L 
 
Recession 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
Enlargement 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
PPD 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
CAL 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 A comparative study on the serum levels of nitric oxide before and after initial 
periodontal therapy in healthy and type 2 diabetes mellitus patients with chronic 
periodontitis 
         Patient record form (Post- treatment) 
 
                               GROUP I / GROUP II/ GROUP III 
 
      Date: 
Name:           Age:                    Sex:  M / F 
 
 
CLINICAL PARAMETERS  
 
I. Oral Hygiene  Index – Simplified (Greene and Vermilion-1964) 
 
     Debris Index-S           Calculus Index-S 
 
 
 
 
 
Score:  
Interpretation: 
 
 
   
16 11 26 
46 31 36 
   
   
16 11 26 
46 31 36 
   
Good  Fair  Poor  
  
II. Gingival Index (Loe and Silness-1963) 
 
 
 
 
 
 
 
 
 
 
Score:  
Interpretation: 
 
 
 
BLOOD INVESTIGATION 
 
NO level: 
 
 
 
         
   
16 12 24 
44 32 36 
   
         
Mild  Moderate  Severe  
  
PERIODONTAL STATUS 
MAXILLA 
 
 
 D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B 
 D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P D.P P M.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P M.P P D.P 
 
Recession 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
Enlargement 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
PPD 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
 
CAL 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
                                                 
                                                 
  
PERIODONTAL STATUS 
MANDIBLE 
 
 D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B D.B B M.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B M.B B D.B 
 D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L D.L L M.L 
 
Recession 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
Enlargement 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
PPD 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
 
CAL 48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                                                 
                                                 
